CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03444766
NCT03444766Phase 4Completed
CompareCT.gov

Safety Study of Nivolumab for Selected Advanced Malignancies in India

Bristol-Myers Squibb·interventional·Posted Feb 23, 2018·Updated Dec 4, 2020

In Brief

A Phase 4 clinical trial evaluating Nivolumab for Non-Small Cell Lung Cancer (NSCLC) and 6 related conditions. Completed, enrolled 100 participants across 9 sites.

Detailed Summary

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 23, 2018
Enrollment StartMar 6, 2018
Primary CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago

Interventions

Nivolumabdrug

specified dose on specified days